177 related articles for article (PubMed ID: 22550168)
1. BEAMing up personalized medicine: mutation detection in blood.
Richardson AL; Iglehart JD
Clin Cancer Res; 2012 Jun; 18(12):3209-11. PubMed ID: 22550168
[TBL] [Abstract][Full Text] [Related]
2. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
[TBL] [Abstract][Full Text] [Related]
3. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
4. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Jelovac D; Beaver JA; Balukrishna S; Wong HY; Toro PV; Cimino-Mathews A; Argani P; Stearns V; Jacobs L; VanDenBerg D; Kessler J; Jeter S; Park BH; Wolff AC
Hum Pathol; 2014 Apr; 45(4):880-3. PubMed ID: 24444464
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
[TBL] [Abstract][Full Text] [Related]
6. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
[TBL] [Abstract][Full Text] [Related]
7. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
8. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
[TBL] [Abstract][Full Text] [Related]
10. Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.
Fu Y; Jovelet C; Filleron T; Pedrero M; Motté N; Boursin Y; Luo Y; Massard C; Campone M; Levy C; Diéras V; Bachelot T; Garrabey J; Soria JC; Lacroix L; André F; Lefebvre C
Cancer Res; 2016 Oct; 76(20):5954-5961. PubMed ID: 27535334
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
[TBL] [Abstract][Full Text] [Related]
12. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
Butler TM; Johnson-Camacho K; Peto M; Wang NJ; Macey TA; Korkola JE; Koppie TM; Corless CL; Gray JW; Spellman PT
PLoS One; 2015; 10(8):e0136407. PubMed ID: 26317216
[TBL] [Abstract][Full Text] [Related]
13. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease.
Romero A; Acosta-Eyzaguirre D; Sanz J; Moreno F; Serrano G; Díaz-Rubio E; Caldés T; Garcia-Saenz JÁ
Transl Res; 2015 Dec; 166(6):783-7. PubMed ID: 26001593
[TBL] [Abstract][Full Text] [Related]
14. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
[TBL] [Abstract][Full Text] [Related]
15. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.
Dupont Jensen J; Laenkholm AV; Knoop A; Ewertz M; Bandaru R; Liu W; Hackl W; Barrett JC; Gardner H
Clin Cancer Res; 2011 Feb; 17(4):667-77. PubMed ID: 20940279
[TBL] [Abstract][Full Text] [Related]
17. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
[TBL] [Abstract][Full Text] [Related]
18. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform.
Kidess E; Heirich K; Wiggin M; Vysotskaia V; Visser BC; Marziali A; Wiedenmann B; Norton JA; Lee M; Jeffrey SS; Poultsides GA
Oncotarget; 2015 Feb; 6(4):2549-61. PubMed ID: 25575824
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.
Toro PV; Erlanger B; Beaver JA; Cochran RL; VanDenBerg DA; Yakim E; Cravero K; Chu D; Zabransky DJ; Wong HY; Croessmann S; Parsons H; Hurley PJ; Lauring J; Park BH
Clin Biochem; 2015 Oct; 48(15):993-8. PubMed ID: 26234639
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
